SELLAS Life Sciences (SLS) Enterprise Value Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.60% |
| Dec 31, 2025 | 69.07% |
| Sep 30, 2025 | -40.14% |
| Jun 30, 2025 | 50.31% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | -168.23% |
| Sep 30, 2024 | 2.76% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 47.78% |
| Dec 31, 2023 | 13.87% |
| Sep 30, 2023 | -108.80% |
| Jun 30, 2023 | 58.97% |
| Mar 31, 2023 | -22.65% |
| Dec 31, 2022 | -6.08% |
| Sep 30, 2022 | 62.17% |
| Jun 30, 2022 | 62.56% |
| Mar 31, 2022 | 64.64% |
| Dec 31, 2021 | -28.70% |
| Sep 30, 2021 | -1.42% |
| Jun 30, 2021 | 65.20% |
| Mar 31, 2021 | -133.78% |
| Dec 31, 2020 | -90.77% |
| Sep 30, 2020 | 25.07% |
| Jun 30, 2020 | 40.77% |
| Mar 31, 2020 | 71.47% |
| Dec 31, 2019 | 66.49% |
| Sep 30, 2019 | 65.82% |
| Jun 30, 2019 | 69.70% |
| Mar 31, 2019 | 45.26% |
| Dec 31, 2018 | 35.49% |
| Sep 30, 2018 | 71.30% |
| Jun 30, 2018 | 16.29% |
| Mar 31, 2018 | 13.20% |
| Dec 31, 2017 | 17.22% |
| Sep 30, 2017 | 24.15% |
| Jun 30, 2017 | 6.70% |
| Mar 31, 2017 | -15.78% |
| Dec 31, 2016 | 33.86% |
| Sep 30, 2016 | -9.33% |
| Jun 30, 2016 | -1.78% |
| Mar 31, 2016 | 48.54% |
| Dec 31, 2015 | 27.33% |
| Sep 30, 2015 | -65.02% |
| Jun 30, 2015 | -54.80% |